Montage of HTDCS in Psycho-cognitive Functions in FM (HFTDCS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04890964 |
Recruitment Status :
Recruiting
First Posted : May 18, 2021
Last Update Posted : May 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Device: Transcranial Direct Current Stimulation (tDCS) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 66 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | HB-a-tDCS - M1 (n=33); HB-s-tDCS - M1 (n=17); HB-a-tDCS-DLPFC (n=33); HB-a-tDCS- DLPFC (n=17) |
Masking: | Triple (Participant, Care Provider, Investigator) |
Masking Description: | A randomized, double-blind, factorial, parallel-group, controlled trial with simulated treatment will be performed. The study follows the CONSORT guideline and will be registered in the ClinicalTrials.gov database: Home |
Primary Purpose: | Treatment |
Official Title: | Mapping the Impact of the Montage of the Transcranial Direct Current Stimulation at Home at Cortical and Psycho-cognitive Functions, Functional Capacity and Biological Rhythm in the Fibromyalgia: A Randomized, Factorial, Clinical Trial |
Actual Study Start Date : | February 1, 2021 |
Estimated Primary Completion Date : | December 10, 2021 |
Estimated Study Completion Date : | December 10, 2022 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC
Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
|
Device: Transcranial Direct Current Stimulation (tDCS)
A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Other Names:
|
Sham Comparator: Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC
Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
|
Device: Transcranial Direct Current Stimulation (tDCS)
A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Other Names:
|
Active Comparator: Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1
Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
|
Device: Transcranial Direct Current Stimulation (tDCS)
A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Other Names:
|
Placebo Comparator: Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1
Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
|
Device: Transcranial Direct Current Stimulation (tDCS)
A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Other Names:
|
- level of pain [ Time Frame: Up to 60 minutes before and after tDCS stimulation ]response on the Numeric Verbal Scale (NPS) from 0-10 during the conditioning stimulus
- Psychocognitive functions [ Time Frame: Pre and Pos 20 days Intervention ]episodic memory measured by Rey Verbal test
- circadian rhythmicity [ Time Frame: Pre and Pos 20 days Intervention ]urinary 6-sulfatoxymelatonin levels
- Effect of tDCS over DLPFC on cognitive function. [ Time Frame: Pre and Pos 20 days Intervention ]Cortical connectivity

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | We have chosen women over men, due to the prevalence of the disease that we are researching and also because the symptoms characteristics are more homogeneous. |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women aged 30 to 65 years; who can read and write, with a confirmed diagnosis of FM according to the criteria of the American College of Rheumatology (2010-2016). Pain score equal to or greater than six on the Numeric Pain Scale (NPS 0-10) on most days in the last 3 months.
Exclusion Criteria:
- Living outside Porto Alegre area and pregnancy.
- Contraindications to TMS and tDCS: metallic implant in the brain; medical devices implanted in the brain, cardiac pacemaker; aneurysmal clip; metallic cochlear prosthesis, ear implants, and non-removable hearing aids; infusion pumps (including implantable); cranial halos. Pregnant women, shift work, use of exogenous melatonin, history of alcohol or drug abuse in the last 6 months, neurological pathologies, history of head trauma or neurosurgery, decompensated systemic chronic diseases, chronic inflammatory diseases (lupus, rheumatoid arthritis, Reiter's syndrome), personal history of cancer, past or under treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04890964
Contact: Wolnei Caumo, Dr. | +555199813977 | wcaumo@hcpa.edu.br |
Brazil | |
Hospital de Clinicas de Porto Alegre | Recruiting |
Porto Alegre, Rio Grande Do Sul, Brazil, 90.450-120 | |
Contact: Wolnei Caumo, PhD +5551 3359 6377 wcaumo@hcpa.edu.br | |
Principal Investigator: Wolnei Caumo, PhD |
Principal Investigator: | Wolnei Caumo, Dr | Hospital de Clinicas de Porto Alegre |
Responsible Party: | Hospital de Clinicas de Porto Alegre |
ClinicalTrials.gov Identifier: | NCT04890964 |
Other Study ID Numbers: |
36995020.3.0000.5327 |
First Posted: | May 18, 2021 Key Record Dates |
Last Update Posted: | May 18, 2021 |
Last Verified: | May 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
fibromyalgia chronic pain tDCS |
TMS BDNF cortical connectivity |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |